WebDoctor Encyclopedia

Article

TRK Inhibitors (Larotrectinib and Entrectinib)

What are TRK inhibitors?

TRK inhibitors are targeted cancer medicines that block abnormal proteins called TRK fusion proteins. The two first drugs of this kind are larotrectinib and entrectinib. Both are taken by mouth as capsules or liquid.

They work only in cancers that carry a specific genetic change called an NTRK gene fusion. This change can occur in many different types of cancer, in both children and adults. For this reason, TRK inhibitors were among the first cancer medicines approved based on a gene change rather than the organ where the cancer started. This is known as a tumour-agnostic or site-agnostic approval.

NTRK fusions are rare in common cancers, usually found in well under 1% of cases. In a few rare cancers, however, they are found in most tumours. For people whose cancer has this change, TRK inhibitors can shrink the cancer dramatically, often with mild side effects.

1. Key facts at a glance

Feature Details
Type of treatment Targeted therapy (kinase inhibitor)
Drugs Larotrectinib, entrectinib; newer drugs such as repotrectinib
Main use Advanced solid tumours with an NTRK gene fusion
Test needed Tumour testing for NTRK fusion
How it is given Capsules or oral liquid, at home
Dosing Larotrectinib twice daily; entrectinib once daily
Course length Continued for as long as it works and is tolerated
Common side effects Dizziness, tiredness, weight gain, changes in taste, constipation, raised liver enzymes

A short history

NTRK fusions were first described in a bowel cancer sample in the 1980s, but for decades there was no way to target them. Larotrectinib was designed specifically to block TRK proteins, while entrectinib was developed to block TRK, ROS1 and ALK. Both received their first approvals in 2018 and 2019, after early trials showed striking responses in children and adults with many different cancers.

2. How it works

The TRK family

TRK proteins (TRKA, TRKB and TRKC) are receptors on nerve cells. They help nerves grow, survive and send signals, and they play a role in pain, appetite and balance. They are made by three genes called NTRK1, NTRK2 and NTRK3.

What goes wrong in cancer

In an NTRK fusion, part of an NTRK gene breaks off and joins to an unrelated gene. The resulting fusion protein is switched on all the time, sending constant “grow and divide” signals inside the cell. The cancer becomes heavily dependent on this signal.

Step Effect
1. Gene fusion Part of an NTRK gene joins another gene
2. Abnormal protein The fusion protein is always active
3. Constant signals Growth pathways inside the cell stay switched on
4. TRK inhibitor The drug fits into the active pocket of the TRK kinase and blocks it
5. Result Growth signals stop and the cancer often shrinks

Larotrectinib and entrectinib compared

Feature Larotrectinib Entrectinib
Targets TRKA, TRKB, TRKC only TRKA, TRKB, TRKC, plus ROS1 and ALK
Dosing Twice daily Once daily
Age Children from birth and adults Children over 1 month in some regions and adults
Brain activity Some activity in the brain Designed to cross into the brain; good activity in brain metastases
Other uses NTRK fusion cancers Also used for ROS1-positive lung cancer

3. Who it is for

TRK inhibitors are used for people whose cancer has an NTRK fusion, usually when the cancer is advanced, cannot be removed safely, or would need surgery that causes serious harm.

Conditions treated

Condition How often NTRK fusions occur
Infantile fibrosarcoma Most tumours, usually ETV6-NTRK3
Congenital mesoblastic nephroma Common in the cellular type
Secretory carcinoma of the salivary gland Most tumours
Secretory carcinoma of the breast Most tumours
Papillary thyroid carcinoma A small proportion, higher in children and after radiation
Soft tissue sarcoma A small proportion of some types
Lung adenocarcinoma Rare
Colorectal adenocarcinoma Rare, mainly in mismatch repair-deficient tumours
Glioblastoma Rare; more frequent in infant brain tumours

Testing for NTRK fusions

Test What it does
Immunohistochemistry (IHC) Screens tumour tissue for TRK protein; a positive result needs confirming
RNA-based next-generation sequencing Most reliable way to detect fusions
DNA-based sequencing panels Detect many fusions, but may miss some
FISH Looks for breaks in a specific gene, often ETV6
Liquid biopsy Searches blood for tumour DNA; a negative result does not rule out a fusion

Ask your team whether your tumour has had comprehensive genetic testing, especially if you have an advanced cancer with limited treatment options.

Why tumour-agnostic approval matters

Traditionally, cancer drugs were tested and approved one cancer type at a time, such as breast cancer or bowel cancer. With rare gene changes like NTRK fusions, it would be almost impossible to run a separate large trial for every tumour type. Instead, the TRK inhibitor trials enrolled people with many different cancers that shared the same fusion. The consistent responses across cancers convinced regulators that the gene change itself was the right target.

This approach has since been used for other medicines. It also means that genetic testing of the tumour has become an important step for many people with advanced cancer, regardless of where the cancer began.

4. Before treatment

Step Why it is done
Confirm NTRK fusion The drugs only work in cancers with the fusion
Blood tests Check liver function, blood counts and uric acid
Heart tracing (ECG) Entrectinib can affect heart rhythm
Medicines review Some medicines and grapefruit interact with these drugs
Weight Baseline, as weight gain is common
Pregnancy test These drugs may harm an unborn baby
Baseline scans To measure response later

5. What to expect: step by step

Step What happens
1. Prescription Your specialist prescribes the drug and dose, based on body size for children
2. Collecting the medicine Usually from a hospital pharmacy
3. Starting at home Swallow capsules whole, or measure the liquid with an oral syringe
4. Regular timing Take at the same times each day, with or without food as advised
5. Early review Clinic visit and blood tests after 2-4 weeks
6. Scans Usually every 2-3 months to check response
7. Ongoing monitoring Blood tests, weight checks and symptom reviews
8. Dose adjustments The dose may be lowered or paused for side effects

Before surgery in children

In some children with infantile fibrosarcoma or other NTRK-driven tumours, a TRK inhibitor is given before surgery to shrink the tumour. This can make an operation much smaller, avoiding amputation or the loss of important structures.

6. Side effects and risks

TRK inhibitors are usually well tolerated. Some side effects arise because TRK proteins also work in normal nerves; these are called on-target effects. A review described dizziness, weight gain and pain on stopping the drug as typical on-target effects (Harada and Drilon, 2022).

Side effect How common Notes
Dizziness and unsteadiness Common Take care with driving and heights
Tiredness Common Often mild
Weight gain Common TRK signals help control appetite
Taste changes Common, especially with entrectinib Usually mild
Constipation or diarrhoea Common Managed with diet and medicines
Raised liver enzymes Common Monitored with blood tests
Anaemia and low white cells Occasional Blood tests
Tingling or numbness Occasional Report to your team
Pain when stopping Possible Called withdrawal pain; can be managed by tapering
Bone fractures Uncommon Reported particularly in children
Heart rhythm changes Rare, with entrectinib ECG monitoring
Memory or mood changes Occasional, with entrectinib Report changes in thinking or mood

7. Results and outlook

Study Main finding
Larotrectinib pooled analysis (159 children and adults) 79% of evaluable patients had their tumours shrink, and 16% had a complete response; serious drug-related side effects were uncommon (Hong et al., 2020)
Entrectinib integrated analysis (54 adults) 57% had their tumours shrink, across ten tumour types (Doebele et al., 2020)
Entrectinib updated analysis (121 adults) About 61% responded; median response lasted 20 months, and brain metastases shrank in about two-thirds of those measured (Demetri et al., 2022)

These response rates are very high for medicines given across many cancer types. Responses are often seen within the first two months, and many last for years.

Resistance

Over time, some cancers develop new mutations in the TRK kinase that stop the drug binding. Next-generation drugs such as repotrectinib and selitrectinib were designed to overcome some of these changes (Harada and Drilon, 2022). If your cancer grows on treatment, a new biopsy or blood test may show why and guide the next step.

8. Recovery and aftercare

Living with long-term treatment

Because TRK inhibitors are often taken for many months or years, managing everyday side effects matters.

Issue Practical tips
Dizziness Stand up slowly; avoid driving if you feel unsteady
Weight gain Regular activity and support from a dietitian
Taste changes Try different flavours and textures
Missed doses Follow the instructions in the patient leaflet; do not double up
Other medicines Always check with a pharmacist before starting new ones
Travel Carry enough medicine and a letter from your team

Follow-up

Check Typical timing
Clinic review Every 4-12 weeks
Blood tests At each review
Scans Every 2-3 months at first
Growth and development in children Regularly

Pregnancy and contraception

TRK inhibitors may harm an unborn baby. Use effective contraception during treatment and for the time advised afterwards, and tell your team straight away if you or your partner become pregnant.

Stopping treatment

In some children whose tumour has disappeared, doctors may consider stopping treatment after a period of time and watching closely. If the cancer returns, the same drug often works again. Adults usually continue as long as the drug is working.

Coping with a rare diagnosis

Learning that your cancer has a rare gene change can feel both hopeful and confusing. You may meet doctors who have treated only a few people with the same fusion. Asking for referral to a specialist centre, a molecular tumour board or a clinical trials unit can help ensure that you receive the most up-to-date options. Patient groups focused on rare cancers and precision medicine can also offer support and information.

9. Alternatives

Alternative When it is considered
Surgery When the tumour can be removed without major harm
Chemotherapy Standard treatments for the specific cancer type
Radiotherapy Local control of a tumour
Other targeted drugs When a different driver change is found
Immunotherapy Some cancers, such as mismatch repair-deficient colorectal cancer
Clinical trials Next-generation TRK inhibitors after resistance

10. Frequently asked questions

Question Answer
Will this drug work for my cancer? Only if your tumour has an NTRK fusion
Is it chemotherapy? No; it is a targeted drug that blocks a specific protein
Will I lose my hair? Hair loss is not typical
Can children take it? Yes; liquid forms and weight-based doses are available
How quickly does it work? Many people respond within the first one to two months
Can I take it with food? Follow the instructions for your specific drug
What if it stops working? Your team may test for resistance mutations and consider a next-generation drug

11. Questions to ask your care team

  • Has my tumour been tested for NTRK fusions?
  • Which TRK inhibitor do you recommend, and why?
  • How will we know if it is working?
  • What side effects should I report straight away?
  • Do any of my other medicines interact with it?
  • How long will I need to take it?
  • What happens if the cancer becomes resistant?

Resources

  1. Demetri, G.D. et al. (2022) ‘Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors’, Clinical Cancer Research, 28(7), pp. 1302-1312.
  2. Doebele, R.C. et al. (2020) ‘Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials’, The Lancet Oncology, 21(2), pp. 271-282.
  3. Harada, G. and Drilon, A. (2022) ‘TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults’, Cancer Genetics, 264-265, pp. 33-39.
  4. Hong, D.S. et al. (2020) ‘Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials’, The Lancet Oncology, 21(4), pp. 531-540.
  5. National Cancer Institute (2026) Larotrectinib Sulfate. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/larotrectinibsulfate (Accessed: October 2026).
  6. National Cancer Institute (2026) Entrectinib. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/entrectinib (Accessed: October 2026).

Prepared by the editorial team, October 2026.